[CAS NO. 1001389-72-5] GSK-1482160
PRODUCTS SPECIFICATIONS [1001389-72-5]
DESCRIPTION [1001389-72-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 334.72 |
| Molecular Formula | C14H14ClF3N2O2 |
| SMILES | O=C([C@H](CC1)N(C)C1=O)NCC2=CC=CC(C(F)(F)F)=C2Cl |
Summary
GSK-1482160 is an orally available negative allosteric modulator of the P2X7 receptor. P2X7 receptors are involved in the production of pro-inflammatory cytokines, such as Il-1β, by central and peripheral immune cells. GSK-1482160 has the potential for the research of inflammation diseases [1] .
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00849134 | GlaxoSmithKline |
Pain, Inflammatory
|
November 17, 2008 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 298.76 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.9876 mL | 14.9379 mL | 29.8757 mL |
| 5 mM | 0.5975 mL | 2.9876 mL | 5.9751 mL |
| 10 mM | 0.2988 mL | 1.4938 mL | 2.9876 mL |
